GLPwatch
Papers (10386)
Page 138 of 174, ranked by citation count.
- Neuroprotective Effects of Liraglutide and/or Rivastigmine Combination on the Rat Hippocampus.
- Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.
- Liraglutide: can it make a difference in the treatment of type 2 diabetes?
- The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review.
- Once-weekly glucagon-like peptide 1 receptor agonists.
- Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study.
- Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial.
- Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity".
- New Drug for Type 2 Diabetes.
- Research digest: pioneering an oral GLP-1 receptor agonist.
- Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.
- Liraglutide as a novel therapeutic for overweight in canines: A clinical study.
- <i>In vitro</i> cellular uptake and insulin secretion studies on INS-1E cells of exendin-4-loaded self-nanoemulsifying drug delivery systems.
- Semaglutide Hype or Hope: Evidence-based Review in Diabesity.
- The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis.
- Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II.
- Patient Perceptions of Ozempic (Semaglutide) for Weight Loss: Mixed Methods Analysis of Online Medication Reviews.
- Network meta-analysis of the risk of dyspepsia and anorexia in patients with type 2 diabetes mellitus induced by glucagon-like peptide 1 receptor agonist hypoglycemic drugs.
- The metabolic effect of combined liraglutide treatment and lifestyle modification on obese adolescents in a tertiary center, Riyadh.
- Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
- Is Liraglutide Associated With Myocardial Protection in ST-Elevation Myocardial Infarction?
- Highlights From AHA 2023-New Risk Calculator, Semaglutide and CVD, and More.
- Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss.
- Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply.
- In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA1c.
- GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk.
- Liraglutide in the management of obesity: real world data (Portugal).
- Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.
- Synthesis of the extracellular domain of GLP-1R by chemical and biotechnological approaches.
- Tirzepatide for Lipodystrophy.
- Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital.
- Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.
- Regulation of nanoparticle exocytosis direction via receptors transfer: A novel strategy to enhance therapeutic efficacy of semaglutide.
- Endoscopic and Open Carpal Tunnel Release in Patients With Type II Diabetes Mellitus: Influence of Preoperative Semaglutide Use on Postoperative Outcomes.
- Combined effect of continuous glucose monitoring and semaglutide: analysis of administrative claims.
- Glucagon-like peptide-1 agonists alleviate adenine-induced nephrotoxicity in rats: interaction with the renin-angiotensin system and role of NLRP-3 inflammasome, nephrin and KIM-1.
- More on Semaglutide in Early Type 1 Diabetes.
- Association learning is impaired in insulin resistance and restored by liraglutide.
- Effects of Liraglutide on Mitigation of Hearing Loss After Repeated Blast Exposures: A Summary of Studies in Animal Model of Chinchilla.
- Differential effects of the anti-obesity drug tirzepatide on adipose tissues: Brown fat as a key target.
- Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis.
- [Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)].
- Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study.
- Comparative study of dulaglutide single-use pen Ateos versus insulin degludec FlexTouch on learning and mock administration time in Japanese patients with type 2 diabetes mellitus - a <i>post-hoc</i> analysis.
- Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements.
- Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.
- Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide.
- A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.
- Artificial intelligence and natural language processing of patient narratives to evaluate semaglutide for weight loss.
- In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
- Semaglutide (Ozempic) for weight loss.
- An analysis of national news coverage of semaglutide for weight loss.
- Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.
- Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few.
- Current challenges in type 2 diabetes.
- Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database.
- Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study.
- Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study.
- Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
- TREATMENT OF DIABETES MELLITUS IN A GOLDEN LION TAMARIN (LEONTOPITHECUS ROSALIA) WITH THE GLUCAGON-LIKE PEPTIDE-1 MIMETIC EXENATIDE.